Pentagalloylglucose down-regulates mast cell surface FcεRI expression in vitro and in vivo

• Published in: FEBS letters 2010-01, Vol.584 (1), p.111-118
• Main Authors: Kageyama-Yahara, Natsuko, Suehiro, Yoko, Maeda, Futoshi, Kageyama, Shun-ichiro, Fukuoka, Junya, Katagiri, Tatsuo, Yamamoto, Takeshi, Kadowaki, Makoto
• Format: Article
• Language: English
• Subjects: 1,2,3,4,6-penta-O-galloyl-β-d-glucose; 1,3,6-tri-O-galloyl-b-d-glucose; Allergy; bovine serum albumin; BSA; colon; diarrhea; dinitrophenyl; DNP; FcεRI; gallic acid; Gene expression; high-affinity IgE receptors; IgE; immunoglobulin E; interleukin; lamina propria mononuclear cell; LPMC; Mast cell; mast cells; mBMMC; mice; mMCP-1; mouse mast cell protease-1; mucosal-type murine bone marrow-derived mast cell; OVA; ovalbumin; pathogenesis; PGG; TGF-β1; TGG; therapeutics; transforming growth factor-β1
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1016/j.febslet.2009.11.007

Mast cell activation by immunoglobulin E (IgE)-mediated stimuli is a central event in the pathogenesis of allergic disorders. The present report shows that treatment with pentagalloylglucose (PGG) resulted in a down-regulation of FcεRI surface expression on mucosal-type murine bone marrow-derived mast cells (mBMMCs), which correlated with a reduction in IgE-mediated activation of mBMMCs. Furthermore, PGG prevented development of allergic diarrhea in a food-allergy mouse model and suppressed the up-regulated FcεRI surface expression on mast cells derived from the food-allergy mouse colon. These findings on PGG suggest its therapeutic potential for allergic diseases through suppressing the FcεRI surface expression.